Gene-ius - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gene-ius


Pharmaceutical Technology Europe
Volume 23, Issue 8


Rich Whitworth
There have been several new stories and reports lately that paint a rather gloomy picture of the state of pharma R&D. From reports on high clinical trial failure rates (see "News") to the CEO of Eli Lilly needing to defend his position on maintaining R&D expenditure to investors, there is a message emerging, and pharma companies, or rather their investors, are beginning to question the future of R&D, and its current inability to stave off losses from patent expiries and generic competition. (I listened with interest to a news story on the radio this morning about common painkillers, such as aspirin and paracetamol, being more efficacious for dementia than antipsychotics — talk about generic competition.)

There was one beacon of light that left me feeling inspired this month, though, unfortunately, it too stems from something of an R&D failure... The Global Genes Fund aims to raise financial support for research into rare diseases, as well as increase awareness. It has a wonderful and simple message: "Every child, everywhere, regardless of disease, deserves treatments, therapies and support." It is common knowledge that the traditional pharma model does not serve orphan diseases well; pharma companies are, of course, more interested in the provision of drugs for the majority to justify R&D costs. But awareness of orphan diseases is steadily increasing, thanks to this project and other campaigns such as Rare Disease Day ( http://rarediseaseday.org/).

The fund is part of the larger US-based Global Genes Project ( http://globalgenesproject.org/), and the aim is that, in the near future, potential donors will be able to peruse research projects and make individual donations online. The idea of connecting the public directly to research activities in this way is interesting and could add incentive to tackling rare diseases. It will no doubt also leverage the vast potential of social networking and "crowdsourcing". I look forward to seeing how it could change the future landscape of R&D.

Best wishes,

Rich Whitworth, Editor

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology Europe,
Click here